查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941123

製藥隔離器市場 - 全球產業規模、佔有率、趨勢、機會及預測（按類型、應用、最終用戶、地區和競爭格局分類，2021-2031年）

Pharmaceutical Isolators Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Type, By Application, By End-User, By Region & Competition, & Competition 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球醫藥隔離器市場預計將從 2025 年的 49.7 億美元成長到 2031 年的 78.2 億美元，複合年成長率達到 7.85%。

這些密封的隔離裝置如同物理屏障，將生產過程與工作人員隔離開來，確保無菌環境並防止交叉污染。推動此產業發展的關鍵因素是嚴格的法規結構，例如歐盟GMP附件1，該框架要求將人員與關鍵的無菌操作分開，以降低風險。此外，高活性藥物原料藥（HPAPI）產量的不斷成長，也使得這些嚴格的隔離措施對於確保工作人員在處理有毒化合物時的安全至關重要。

市場概覽
預測期 2027-2031
市場規模：2025年 49.7億美元
市場規模：2031年 78.2億美元
複合年成長率：2026-2031年 7.85%
成長最快的細分市場 無菌隔離器
最大的市場 北美洲

然而，由於改造現有生產線需要大量的資本投入和技術複雜性，市場面臨許多障礙。中小製造商往往因為升級老舊設備所需的成本和運作而面臨重重阻礙。根據靜脈注射藥物協會 (PDA) 2024 年的一項調查，儘管 75% 的公司能夠按時完成監管要求，但隔離技術在合規方面仍然是一個主要滯後領域。這種普及率的差距凸顯了採用隔離器技術所面臨的營運和財務挑戰。

市場促進因素

無菌生產的嚴格監管要求，特別是歐盟GMP附錄1的實施，是全球製藥隔離器市場的主要驅動力。該法規明確要求將人員與關鍵的無菌流程隔離，以最大限度地降低污染風險，從而推動了從傳統潔淨室轉向先進屏障技術的轉變。這種轉變也體現在主要產業參與者的財務表現。例如，SKAN集團在其2024年半年報告中指出，淨銷售額成長17.2%，達到1.637億瑞士法郎，並將這一成長歸功於行業向更先進的隔離器技術的結構性轉變。因此，監管壓力使得隔離器成為在無菌環境中實現合規的必備設備，而非可選項。

此外，對高活性藥物原料藥（HPAPI）的需求不斷成長，正在重塑市場需求，因為處理這些有毒化合物需要嚴格的隔離策略來保護工作人員。隨著製藥研發管線聚焦於抗體藥物複合體（ADC）等腫瘤療法，對具備納克級隔離能力的設備的需求正在迅速成長。為此，Sterling Pharma Solutions在2024年5月的新聞稿中宣布，將投資300萬美元，用於建造一套配備模組化隔離器的GMP運作車間，其隔離能力低於每立方公尺1納克。此舉與擴大無菌生產能力的更廣泛趨勢相呼應。三星生物製劑公司2024年創紀錄的4.55兆韓元年收入便印證了這一點，其生物製造工廠的高運轉率推動了23%的同比成長。

市場挑戰

全球製藥隔離器市場的擴張受到現有生產線維修所需高額資本投入和技術複雜性的顯著限制。將先進的隔離系統整合到現有設施中，需要在設備和結構維修進行大量前期投資。這個過程通常會導致長時間的生產停機，造成中小型製造商難以承受的收入損失。此外，在狹小空間內安裝這些系統所需的複雜工程設計也增加了財務和營運負擔，使現代化改造計劃風險高、資源消耗大。

由於企業不願打破既有的工作流程，這些財務和技術方面的障礙共同阻礙了隔離技術的普及。近期行業調查結果也印證了此類複雜投資難以獲得合理性。 2024年，國際製藥工程協會（ISPE）的數據顯示，48%的製藥專業人士認為監管和技術的挑戰是阻礙他們投資創新生產解決方案的主要因素。這項數據凸顯了企業在面臨高昂的實施成本和嚴格的合規要求雙重壓力時，對設備升級的猶豫不決。

市場趨勢

將機械臂整合到無手套無菌處理中正成為一種變革性趨勢，有效消除了人為干預這一主要污染源。透過用全自動機器人操作取代傳統的手套端口，製造商可以確保絕對的無菌性和卓越的精度，這對於敏感生物製藥至關重要。隨著企業尋求對傳統工作流程進行現代化改造以最大限度降低風險，這種向「無人操作」環境的轉變正受到廣泛關注。根據CRB於2024年10月發布的《展望：生命科學2024》報告，91%的受訪製藥專業人士認為無人操作灌裝技術是藥品生產的未來發展方向，這標誌著傳統屏障系統的明顯退化。

同時，專為細胞和基因療法 (CGT) 生產而設計的隔離器發展呈現出顯著趨勢，這類產品需要超小規模批量生產和零產品損失。與用於生產重磅藥物的高速生產線不同，這些先進的隔離器旨在處理高價值的個人化療法，因為每一滴都至關重要。這種發展趨勢解決了先進治療產品 (ATMP) 特有的操作限制，例如頻繁的換線和最大化產量。正如 Syntegon 在 2024 年 5 月發布的關於其為 Kindeva Drug Delivery 提供的設備的新聞稿中所強調的那樣，該公司的新型生產單元體現了這種能力，其灌裝能力為每小時 120 至 500 個單位，專為滿足小規模、高活性生產的精確要求而量身定做。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球製藥隔離器市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（封閉式隔離器、開放式隔離器）
    • 依應用領域（無菌隔離器、密閉隔離器等）
    • 依最終用戶（製藥/生技公司、研究機構等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美製藥隔離器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲製藥隔離器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區製藥隔離器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲製藥隔離器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲製藥隔離器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球製藥隔離器市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Getinge AB
  • Fedegari Autoclavi SpA
  • IMA Group
  • Bosch Packaging Technology
  • COMECER SpA
  • SKAN AG
  • Germfree Laboratories Inc.
  • MBRAUN GmbH
  • LAF Technologies Pty Ltd.
  • Wabash National Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 17531

The Global Pharmaceutical Isolators Market is projected to expand from USD 4.97 Billion in 2025 to USD 7.82 Billion by 2031, achieving a compound annual growth rate of 7.85%. These sealed containment devices serve as physical barriers between manufacturing processes and operators, ensuring sterility and preventing cross-contamination. Growth is primarily driven by strict regulatory frameworks, such as the EU GMP Annex 1, which necessitates separating personnel from critical aseptic operations to lower risk. Additionally, the increasing production of High Potency Active Pharmaceutical Ingredients (HPAPIs) mandates these rigorous containment measures to ensure operator safety during the handling of toxic compounds.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.97 Billion
Market Size 2031USD 7.82 Billion
CAGR 2026-20317.85%
Fastest Growing SegmentAseptic Isolators
Largest MarketNorth America

However, the market faces significant hurdles due to the high capital expenditure and technical complexity involved in retrofitting existing production lines. Small and mid-sized manufacturers often find the costs and downtime required to upgrade legacy facilities prohibitive. According to a 2024 survey by the Parenteral Drug Association, barrier technologies remained a leading lagging area for compliance, despite 75% of firms meeting general regulatory deadlines. This implementation gap highlights the operational and financial challenges associated with adopting isolation technology.

Market Driver

Stringent regulatory mandates for aseptic manufacturing, specifically the enforcement of the EU GMP Annex 1, act as a primary catalyst for the Global Pharmaceutical Isolators Market. This regulation explicitly requires the separation of personnel from critical aseptic processes to minimize contamination risks, compelling a transition from traditional cleanrooms to advanced barrier technologies. This shift is reflected in the financial performance of key industry players; for instance, the SKAN Group reported in their 'Half-Year Report 2024' that net sales increased by 17.2% to CHF 163.7 million, a growth trajectory attributed to the industry's structural move toward superior isolator technology. Consequently, regulatory pressure has made isolators essential rather than optional for compliance in sterile environments.

The rising demand for High-Potency Active Pharmaceutical Ingredients (HPAPIs) is also reshaping market requirements, as handling these toxic compounds demands rigorous containment strategies to protect operators. With pharmaceutical pipelines increasingly focusing on oncology treatments such as Antibody-Drug Conjugates (ADCs), the need for equipment capable of nanogram-level containment has intensified. In support of this, Sterling Pharma Solutions announced in a May 2024 press release a $3 million investment to commission a GMP suite featuring a modular isolator with containment capabilities down to less than 1 nanogram per cubic meter. This trend parallels the broader expansion of sterile manufacturing capacities, as evidenced by Samsung Biologics reporting a record annual revenue of 4.55 trillion Korean won for 2024, representing a 23% year-on-year growth driven by high utilization of its biomanufacturing plants.

Market Challenge

The expansion of the Global Pharmaceutical Isolators Market is significantly hampered by the high capital expenditure and technical complexity associated with retrofitting existing production lines. Integrating advanced containment systems into legacy facilities requires substantial upfront investment for both equipment and structural modifications. This process often necessitates extended production downtime, leading to revenue losses that are difficult for small and mid-sized manufacturers to absorb. Furthermore, the intricate engineering required to install these systems within constrained spaces exacerbates the financial and operational burden, making modernization projects risky and resource-intensive.

These financial and technical hurdles collectively slow the adoption rate of isolation technology, as companies hesitate to disrupt established workflows. The difficulty of justifying such complex investments is evident in recent industry findings. In 2024, the International Society for Pharmaceutical Engineering (ISPE) revealed that 48% of pharmaceutical professionals cited regulatory and technical challenges as significant disincentives for investing in innovative manufacturing solutions. This statistic underscores the hesitation among firms to commit to upgrading facilities when faced with the dual pressures of high implementation costs and rigorous compliance requirements.

Market Trends

The integration of robotic arms for gloveless aseptic processing is emerging as a transformative trend, effectively eliminating human intervention as the primary source of contamination. By replacing traditional glove ports with fully automated robotic handling, manufacturers can ensure absolute sterility assurance and superior precision, which is critical for sensitive biologics. This shift toward "operator-free" environments is gaining substantial traction as companies seek to modernize legacy workflows to minimize risk. According to the 'Horizons: Life Sciences 2024' report by CRB published in October 2024, 91% of surveyed pharmaceutical professionals identified operator-free filling as the definitive future of drug product manufacturing, signaling a decisive move away from conventional barrier systems.

Simultaneously, there is a distinct trend toward developing isolators specialized for Cell and Gene Therapy (CGT) manufacturing, which demands equipment tailored for ultra-small batch sizes and zero product loss. Unlike high-speed lines designed for blockbuster drugs, these advanced isolators are engineered to handle high-value, personalized therapies where every drop of product is critical. This evolution addresses the unique operational constraints of ATMPs, such as the need for frequent changeovers and maximum yield preservation. As highlighted in a May 2024 press release by Syntegon regarding an installation for Kindeva Drug Delivery, their new production cell exemplifies this capability by filling between 120 and 500 units per hour, specifically targeting the precision requirements of small-scale and high-potency production.

Key Market Players

  • Getinge AB
  • Fedegari Autoclavi SpA
  • IMA Group
  • Bosch Packaging Technology
  • COMECER S.p.A
  • SKAN AG
  • Germfree Laboratories Inc.
  • MBRAUN GmbH
  • LAF Technologies Pty Ltd.
  • Wabash National Corporation

Report Scope

In this report, the Global Pharmaceutical Isolators Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Isolators Market, By Type

  • Closed Isolators
  • Open Isolators

Pharmaceutical Isolators Market, By Application

  • Aseptic isolators
  • Containment isolators
  • Others

Pharmaceutical Isolators Market, By End-User

  • Pharmaceutical & biotech companies
  • Research laboratories
  • Others

Pharmaceutical Isolators Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Isolators Market.

Available Customizations:

Global Pharmaceutical Isolators Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Isolators Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Closed Isolators, Open Isolators)
    • 5.2.2. By Application (Aseptic isolators, Containment isolators, Others)
    • 5.2.3. By End-User (Pharmaceutical & biotech companies, Research laboratories, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Pharmaceutical Isolators Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End-User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmaceutical Isolators Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End-User
    • 6.3.2. Canada Pharmaceutical Isolators Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End-User
    • 6.3.3. Mexico Pharmaceutical Isolators Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End-User

7. Europe Pharmaceutical Isolators Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End-User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmaceutical Isolators Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End-User
    • 7.3.2. France Pharmaceutical Isolators Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End-User
    • 7.3.3. United Kingdom Pharmaceutical Isolators Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End-User
    • 7.3.4. Italy Pharmaceutical Isolators Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End-User
    • 7.3.5. Spain Pharmaceutical Isolators Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End-User

8. Asia Pacific Pharmaceutical Isolators Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End-User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmaceutical Isolators Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End-User
    • 8.3.2. India Pharmaceutical Isolators Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End-User
    • 8.3.3. Japan Pharmaceutical Isolators Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End-User
    • 8.3.4. South Korea Pharmaceutical Isolators Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End-User
    • 8.3.5. Australia Pharmaceutical Isolators Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End-User

9. Middle East & Africa Pharmaceutical Isolators Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End-User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmaceutical Isolators Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End-User
    • 9.3.2. UAE Pharmaceutical Isolators Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End-User
    • 9.3.3. South Africa Pharmaceutical Isolators Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End-User

10. South America Pharmaceutical Isolators Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End-User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmaceutical Isolators Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End-User
    • 10.3.2. Colombia Pharmaceutical Isolators Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End-User
    • 10.3.3. Argentina Pharmaceutical Isolators Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End-User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmaceutical Isolators Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Getinge AB
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Fedegari Autoclavi SpA
  • 15.3. IMA Group
  • 15.4. Bosch Packaging Technology
  • 15.5. COMECER S.p.A
  • 15.6. SKAN AG
  • 15.7. Germfree Laboratories Inc.
  • 15.8. MBRAUN GmbH
  • 15.9. LAF Technologies Pty Ltd.
  • 15.10. Wabash National Corporation

16. Strategic Recommendations

17. About Us & Disclaimer